Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?

S. T. Lim, M. Tao, Y. B. Cheung, Sandeep Rajan, B. Mann

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Data on the incidence of bone marrow (BM) involvement in early-stage diffuse large B-cell lymphoma (DLBCL) are lacking. Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL. Patients and methods: One hundred and ninety-two patients with radiological stages 1 and 2 disease were analysed. The data collected were age, sex, presence of B symptoms, white blood cell (WBC) count, platelet count, haemoglobin (Hb), serum lactate dehydrogenase level, serum β2-microglobulin level, presence of extranodal disease, and the presence of bulky disease (defined as >7 cm). Results: Overall incidence of BM involvement was 3.6%. Hb < 10g/dl (P=0.02), WBC count <4 × 109/l (P=0.007) and bulky disease (P=0.06) were found to be predictive of BM involvement. Among the 120 patients without any of these three factors, only one patient had BM involvement (0.83%; 95% confidence interval 0.02% to 4.6%). The absence of all three factors gave a negative predictive value of 99.2%. Overall 3-year survival for patients without all three risk factors was 80%. Conclusions: BM biopsy may be safely omitted in selected patients with early-stage DLBCL.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalAnnals of Oncology
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Bone Marrow
Biopsy
Leukocyte Count
Incidence
Hemoglobins
Serum
Platelet Count
L-Lactate Dehydrogenase
Confidence Intervals
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? / Lim, S. T.; Tao, M.; Cheung, Y. B.; Rajan, Sandeep; Mann, B.

In: Annals of Oncology, Vol. 16, No. 2, 01.02.2005, p. 215-218.

Research output: Contribution to journalArticle

Lim, S. T. ; Tao, M. ; Cheung, Y. B. ; Rajan, Sandeep ; Mann, B. / Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?. In: Annals of Oncology. 2005 ; Vol. 16, No. 2. pp. 215-218.
@article{1af98bebc6e042a08799c50bb38c8d8b,
title = "Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?",
abstract = "Background: Data on the incidence of bone marrow (BM) involvement in early-stage diffuse large B-cell lymphoma (DLBCL) are lacking. Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL. Patients and methods: One hundred and ninety-two patients with radiological stages 1 and 2 disease were analysed. The data collected were age, sex, presence of B symptoms, white blood cell (WBC) count, platelet count, haemoglobin (Hb), serum lactate dehydrogenase level, serum β2-microglobulin level, presence of extranodal disease, and the presence of bulky disease (defined as >7 cm). Results: Overall incidence of BM involvement was 3.6{\%}. Hb < 10g/dl (P=0.02), WBC count <4 × 109/l (P=0.007) and bulky disease (P=0.06) were found to be predictive of BM involvement. Among the 120 patients without any of these three factors, only one patient had BM involvement (0.83{\%}; 95{\%} confidence interval 0.02{\%} to 4.6{\%}). The absence of all three factors gave a negative predictive value of 99.2{\%}. Overall 3-year survival for patients without all three risk factors was 80{\%}. Conclusions: BM biopsy may be safely omitted in selected patients with early-stage DLBCL.",
author = "Lim, {S. T.} and M. Tao and Cheung, {Y. B.} and Sandeep Rajan and B. Mann",
year = "2005",
month = "2",
day = "1",
doi = "10.1093/annonc/mdi050",
language = "English (US)",
volume = "16",
pages = "215--218",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?

AU - Lim, S. T.

AU - Tao, M.

AU - Cheung, Y. B.

AU - Rajan, Sandeep

AU - Mann, B.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background: Data on the incidence of bone marrow (BM) involvement in early-stage diffuse large B-cell lymphoma (DLBCL) are lacking. Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL. Patients and methods: One hundred and ninety-two patients with radiological stages 1 and 2 disease were analysed. The data collected were age, sex, presence of B symptoms, white blood cell (WBC) count, platelet count, haemoglobin (Hb), serum lactate dehydrogenase level, serum β2-microglobulin level, presence of extranodal disease, and the presence of bulky disease (defined as >7 cm). Results: Overall incidence of BM involvement was 3.6%. Hb < 10g/dl (P=0.02), WBC count <4 × 109/l (P=0.007) and bulky disease (P=0.06) were found to be predictive of BM involvement. Among the 120 patients without any of these three factors, only one patient had BM involvement (0.83%; 95% confidence interval 0.02% to 4.6%). The absence of all three factors gave a negative predictive value of 99.2%. Overall 3-year survival for patients without all three risk factors was 80%. Conclusions: BM biopsy may be safely omitted in selected patients with early-stage DLBCL.

AB - Background: Data on the incidence of bone marrow (BM) involvement in early-stage diffuse large B-cell lymphoma (DLBCL) are lacking. Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL. Patients and methods: One hundred and ninety-two patients with radiological stages 1 and 2 disease were analysed. The data collected were age, sex, presence of B symptoms, white blood cell (WBC) count, platelet count, haemoglobin (Hb), serum lactate dehydrogenase level, serum β2-microglobulin level, presence of extranodal disease, and the presence of bulky disease (defined as >7 cm). Results: Overall incidence of BM involvement was 3.6%. Hb < 10g/dl (P=0.02), WBC count <4 × 109/l (P=0.007) and bulky disease (P=0.06) were found to be predictive of BM involvement. Among the 120 patients without any of these three factors, only one patient had BM involvement (0.83%; 95% confidence interval 0.02% to 4.6%). The absence of all three factors gave a negative predictive value of 99.2%. Overall 3-year survival for patients without all three risk factors was 80%. Conclusions: BM biopsy may be safely omitted in selected patients with early-stage DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=14644439866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644439866&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi050

DO - 10.1093/annonc/mdi050

M3 - Article

VL - 16

SP - 215

EP - 218

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -